Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
24 September, 2018 10:44 IST
Glenmark initiates phase 2b clinical trial of GBR 830
Source: IRIS | 17 Apr, 2018, 10.04AM
Comments  |  Post Comment

Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the initiation of a Phase 2b clinical trial of GBR 830, a novel, investigational treatment for moderate-to-severe atopic dermatitis. The trial's primary endpoint will assess the efficacy of GBR 830, compared to placebo. Secondary and exploratory trial endpoints include additional measures of efficacy, safety and pharmacodynamics. Trial enrollment is expected to begin in June 2018.

''The results of the Phase 2a trial completed last year demonstrated that GBR 830 was well-tolerated, and suggested signals of efficacy in the treatment of moderate-to-severe atopic dermatitis,'' said Fred Grossman, President and Chief Medical Officer at Glenmark Pharmaceuticals. (Q,N,C,F)* ''We are very pleased to rapidly advance the GBR 830 development program in atopic dermatitis as there is a need for effective and well-tolerated treatments.''

The Phase 2b, double-blind, placebo-controlled multicenter trial will randomize approximately 392 patients across four dosing arms of GBR 830 and placebo. The trial's primary endpoint will assess the effectiveness of GBR 830, compared to placebo, on reducing the severity of atopic dermatitis as measured by Investigator's Global Assessment (IGA). Secondary efficacy measures include patients with a greater than 75% improvement in disease severity, as measured by the Eczema Area and Severity Index (EASI), along with other measures including disease activity using validated assessment tools such as EASI response, and Scoring Atopic Dermatitis (SCORAD). The trial will also assess safety, and biomarkers relevant to the disease and unique mechanism of GBR 830.

''The initiation of this trial is a meaningful milestone in pursuit of a potentially new treatment for a disease with significant unmet need,'' said Kurt Stoeckli, President and Chief Scientific Officer at Glenmark Pharmaceuticals. ''It is also an exciting step for the many scientists who contributed to the discovery of GBR 830, Glenmark's first new biologic entity developed in-house at Glenmark.''

In addition to moderate-to-severe atopic dermatitis, Glenmark is evaluating the potential for conducting studies with GBR 830 for the treatment of other inflammatory autoimmune conditions where dysregulation of OX40 overexpression is implicated in disease activity. Preparations for a clinical trial assessing GBR 830 for the treatment of systemic lupus erythematosus (SLE) are currently underway.

Shares of the company declined Rs 2.05, or 0.35%, to trade at Rs 579.65. The total volume of shares traded was 4,783 at the BSE (9.52 a.m., Tuesday).

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Company Update
Tatas to acquire Usha Martin's steel business for up to Rs 47 bn - 24-Sep-2018 10:05
Sequent Scientific to acquire Solara Active Pharma Sciences' EU-GMP API facility - 24-Sep-2018 09:48
Biocon announces successful USFDA inspection of its Bangalore facility - 24-Sep-2018 09:45
Godrej Properties adds a new residential project in Noida, NCR - 24-Sep-2018 09:42
ITD Cementation India wins orders worth Rs 8.45 bn - 21-Sep-2018 15:44
Emami Paper Mills to invest around Rs 20 bn in Gujarat - 21-Sep-2018 15:03
Tijaria Polypipes receives single order worth Rs 353 mn - 21-Sep-2018 13:13
Infosys to open technology and innovation hub in Arizona - 21-Sep-2018 13:08
Pennar Group bags orders worth Rs 1.81 bn - 21-Sep-2018 13:05
TCS recognized as leader in finance and accounting digital augmentation suite - 21-Sep-2018 12:30
Sun Pharma announces Australian TGA approval of ILUMYA - 21-Sep-2018 12:06
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer